Entera Bio (NASDAQ:ENTX) Stock Price Up 5.2% – Here’s Why

Entera Bio Ltd. (NASDAQ:ENTX) traded up 5.2% on Wednesday . The stock traded as high as $3.05 and last traded at $3.01. Approximately 434,847 shares traded hands during trading, a decline of 59% from the average session volume of 1,054,112 shares. The stock had previously closed at $2.86.

Analysts Set New Price Targets

ENTX has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. Wall Street Zen raised Entera Bio to a “sell” rating in a research report on Saturday, August 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Entera Bio in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $9.00.

Entera Bio Trading Up 3.4%

The company has a market cap of $514.02 million, a PE ratio of -8.42 and a beta of 1.38. The business’s 50-day simple moving average is $2.71 and its 200-day simple moving average is $1.78.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06).

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Entera Bio stock. Seven Fleet Capital Management LP purchased a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 135,318 shares of the company’s stock, valued at approximately $263,000. Seven Fleet Capital Management LP owned approximately 0.30% of Entera Bio at the end of the most recent reporting period. 14.11% of the stock is owned by institutional investors.

Entera Bio Company Profile

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.